Table 1.

Demographic data, clinical characteristics and previous treatments the patients received before vaccination

Patient	Age/sex	Cancer type	Stage	Ras mutation	Prior treatment	Time from prior Tx to vaccine (months)
1	50/M	Colorectal	IV	Asp	Hemicolectomy, 5-FU/LV for 6 months, followed by resection of abdominal wall mass	10
2	57/F	Colorectal	IV	Asp	5-FU/LV for 12 months	5
3	49/M	Pancreas	III	Asp	Whipple, XRT for 1 month, 5-FU/LV for 6 months	12
4	64/M	Colorectal	III	Asp	Left hemicolectomy, 5-FU/LV for 6 months	8
5	71/F	Pancreas	III	Asp	Partial pancreatectomy	6
6	68/F	Pancreas	III	Asp	Whipple with IORT, concurrent XRT/5-FU for 5 weeks, gemcitabine for 6 months	5
7	49/M	Pancreas	III	Val	Whipple, 5-FU for 1 month, then concurrent XRT/5-FU for 1 month, then 5-FU for 3 months	4
8	56/F	Colorectal	III	Asp	Hemicolectomy, 5-FU/LV for 6 months	5
9	38/M	Colorectal	IV	Asp	Right hemicolectomy, camptosar/5-FU/LV for 6 months, cervical lymph node metastectomy, cervical XRT	1.5
10	67/M	Pancreas	II	Val	Whipple	1.5
11	57/F	Colorectal	III	Asp	Hemicolectomy, 5-FU/LV for 6 months	10
12	43/F	Colorectal	III	Asp	Segmental resection of the transverse colon, 5-FU/LV for 6 months	2

M male, F female, Asp patient has the ras mutation in codon 12 Gly to Asp, Val patient has the ras mutation in codon 12 Gly to Va, 5-FU 5-fluorouracil, LV leucovorin, XRT radiotherapy, IORT intraoperative radiotherapy